PAMIDRONATE DISODIUM

Post-LOE

pamidronate disodium

Viatris (2)

ANDAINJECTIONINJECTABLE

Approved

Oct 2008

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

PAMIDRONATE DISODIUM (pamidronate disodium) by Viatris (2) is resorption. Approved for moderate, severe hypercalcemia associated with malignancy, with and 6 more indications. First approved in 2008.

Drug data last refreshed 18h ago

Mechanism of Action

resorption. Although the mechanism of antiresorptive action is not completely understood, several factors are thought to contribute to this action. Pamidronate disodium adsorbs to calcium phosphate (hydroxyapatite) crystals in bone and may block dissolution of this mineral component of bone. In…

Indications (7)

moderate severe hypercalcemia associated with malignancy

Worked on PAMIDRONATE DISODIUM at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.